403 related articles for article (PubMed ID: 32222891)
21. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?
Koletsa T; Kotoula V; Koliou GA; Manousou K; Chrisafi S; Zagouri F; Sotiropoulou M; Pentheroudakis G; Papoudou-Bai A; Christodoulou C; Xepapadakis G; Zografos G; Petraki K; Pazarli E; Koutras A; Kourea HP; Bafaloukos D; Chatzopoulos K; Iliadis A; Markopoulos C; Venizelos V; Arnogiannaki N; Kalogeras KT; Kostopoulos I; Gogas H; Fountzilas G
Cancer Immunol Immunother; 2020 Aug; 69(8):1549-1564. PubMed ID: 32303794
[TBL] [Abstract][Full Text] [Related]
23. Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study.
Zeppellini A; Galimberti S; Leone BE; Pacifico C; Riva F; Cicchiello F; Capici S; Maggioni C; Sala L; Cazzaniga ME
BMC Cancer; 2021 Mar; 21(1):260. PubMed ID: 33691674
[TBL] [Abstract][Full Text] [Related]
24. Composition and plasticity of triple-negative breast carcinoma-infiltrating regulatory T cells.
Cai B; Ma P; Ding P; Sun DW; Bu Q; Zhang J
APMIS; 2020 Mar; 128(3):260-269. PubMed ID: 31811667
[TBL] [Abstract][Full Text] [Related]
25. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
26. The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer.
Goto R; Hirota Y; Aruga T; Horiguchi S; Miura S; Nakamura S; Takimoto M
Breast Cancer; 2020 Jul; 27(4):586-593. PubMed ID: 31933123
[TBL] [Abstract][Full Text] [Related]
27. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G
Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
29. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
30. [CD8 and FOXP3 expression in stromal tumor-infiltrating lymphocytes of triple-negative breast carcinomas: a clinicopathologic study].
Pan BJ; Ping GQ; Zhang WM; Wang C; Li HX; Zhang ZH
Zhonghua Bing Li Xue Za Zhi; 2016 Aug; 45(8):540-4. PubMed ID: 27510779
[TBL] [Abstract][Full Text] [Related]
31. Optimized tumour infiltrating lymphocyte assessment for triple negative breast cancer prognostics.
Balkenhol MC; Ciompi F; Świderska-Chadaj Ż; van de Loo R; Intezar M; Otte-Höller I; Geijs D; Lotz J; Weiss N; de Bel T; Litjens G; Bult P; van der Laak JA
Breast; 2021 Apr; 56():78-87. PubMed ID: 33640523
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.
Althobiti M; Aleskandarany MA; Joseph C; Toss M; Mongan N; Diez-Rodriguez M; Nolan CC; Ashankyty I; Ellis IO; Green AR; Rakha EA
Histopathology; 2018 Dec; 73(6):887-896. PubMed ID: 29947077
[TBL] [Abstract][Full Text] [Related]
33. Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients.
Ahmadvand S; Faghih Z; Montazer M; Safaei A; Mokhtari M; Jafari P; Talei AR; Tahmasebi S; Ghaderi A
Cell Oncol (Dordr); 2019 Jun; 42(3):343-356. PubMed ID: 30825183
[TBL] [Abstract][Full Text] [Related]
34. No effect of tumor-infiltrating lymphocytes (TILs) on prognosis in patients with early triple-negative breast cancer: Validation of recommendations by the International TILs Working Group 2014.
Park HS; Heo I; Kim JY; Kim S; Nam S; Park S; Kim SI
J Surg Oncol; 2016 Jul; 114(1):17-21. PubMed ID: 27157771
[TBL] [Abstract][Full Text] [Related]
35. Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response.
Shin SJ; Kim SY; Choi YY; Son T; Cheong JH; Hyung WJ; Noh SH; Park CG; Kim HI
Oncologist; 2019 Sep; 24(9):e835-e844. PubMed ID: 30894409
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
37. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
38. Presence of myxoid stromal change and fibrotic focus in pathological examination are prognostic factors of triple-negative breast cancer: Results from a retrospective single-center study.
Yanai H; Yoshikawa K; Ishida M; Tsuta K; Sekimoto M; Sugie T
PLoS One; 2021; 16(2):e0245725. PubMed ID: 33571189
[TBL] [Abstract][Full Text] [Related]
39. Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer.
Ahn S; Chung YR; Seo AN; Kim M; Woo JW; Park SY
PLoS One; 2020; 15(5):e0233037. PubMed ID: 32401825
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors.
Baram T; Erlichman N; Dadiani M; Balint-Lahat N; Pavlovski A; Meshel T; Morzaev-Sulzbach D; Gal-Yam EN; Barshack I; Ben-Baruch A
Cells; 2021 Jun; 10(6):. PubMed ID: 34201054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
